Sudarshan Pharma

Has Sudarshan Pharma declared dividend?

Sudarshan Pharma Industries Ltd has declared a 3% dividend, amounting to 0.3 per share, with an ex-date of August 25, 2023. Despite this, the dividend yield is 0%, and the total returns over the last six months are -26.55%, while the past year shows a significant gain of 367.73%.

Sudarshan Pharma Industries Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Amount per share: 0.3<BR>- Ex-date: 25 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -26.55%, with a dividend return of 0%, resulting in a total return of -26.55%.<BR><BR>In the past year, the price return was 367.73%, with a dividend return of 0%, leading to a total return of 367.73%.<BR><BR>Over 2 years, the price return was 360.75%, with a dividend return of 0%, resulting in a total return of 360.75%.<BR><BR>For the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, with a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return, no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sudarshan Pharma has declared a dividend, the dividend yield remains at 0%. The total returns show significant gains over the past year and two years, but recent performance over the last six months has been negative.

Who are the peers of the Sudarshan Pharma?

Sudarshan Pharma's peers include Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Nitta Gelatin, DMCC Speciality, Amal, and Kronox Lab. Sudarshan Pharma leads in 1-year returns at 355.66%, while Deepak Nitrite has the lowest at -9.57%.

Peers: The peers of Sudarshan Pharma are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Nitta Gelatin, DMCC Speciality, Amal, and Kronox Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite, while Good management risk is found at Pidilite Inds. and SRF. Average management risk is present in Gujarat Fluoroch, Himadri Special, Nitta Gelatin, DMCC Speciality, Amal, and Kronox Lab. Sudarshan Pharma and the rest have Below Average growth, with Excellent growth seen at Sudarshan Pharma, Good growth at Himadri Special and Amal, and Average growth at Nitta Gelatin and the rest. Capital Structure is Excellent at Pidilite Inds., SRF, and Kronox Lab, Good at Gujarat Fluoroch, Himadri Special, and DMCC Speciality, Average at Amal, and Below Average at Sudarshan Pharma.<BR><BR>Return Snapshot: Sudarshan Pharma has a 1-year return of 355.66%, which is the highest among its peers, while Deepak Nitrite has the lowest at -9.57%. Sudarshan Pharma's return significantly exceeds all peers. Additionally, the peers with negative six-month returns include Deepak Nitrite, DMCC Speciality, and Sunshield Chem.

Who are in the management team of Sudarshan Pharma?

As of February 2021, the management team of Sudarshan Pharma includes Hemal V Mehta (Managing Director), Sachin V Mehta (Joint Managing Director & CFO), Ujwala Vilas Salvi, Subhash Goverdhandasji Bissa, and Rushabh Prashant Patil (Additional Director). They are responsible for the company's leadership and strategic direction.

As of February 2021, the management team of Sudarshan Pharma includes the following individuals:<BR><BR>1. Hemal V Mehta - Managing Director<BR>2. Sachin V Mehta - Joint Managing Director & CFO<BR>3. Ujwala Vilas Salvi - Director<BR>4. Subhash Goverdhandasji Bissa - Director<BR>5. Rushabh Prashant Patil - Additional Director<BR><BR>These members play key roles in the leadership and strategic direction of the company.

What does Sudarshan Pharma do?

Sudarshan Pharma Industries Ltd is a micro-cap company in the specialty chemicals industry, incorporated in 2008 and previously known as Sudarshan Specialty Chemsolve. It has no recent sales or profit data, with a market cap of INR 702 Cr and a P/E ratio of 39.00.

Overview: <BR>Sudarshan Pharma Industries Ltd operates in the specialty chemicals industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was initially incorporated in 2008 as "Sudarshan Specialty Chemsolve Private Limited" and later changed its name to "Sudarshan Pharma Industries Private Limited" in December 2016. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 702 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 39.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.34 <BR>Return on Equity: 14.11% <BR>Price-to-Book: 5.50 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Sudarshan Pharma?

The top shareholders of Sudarshan Pharma include promoter Sachin Vasantrai Mehta with 27.51%, 11 Foreign Institutional Investors holding 18.45%, and public shareholder Multitude Growth Funds Limited at 5.52%. Individual investors own 18.18% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sudarshan Pharma include the promoters, with Sachin Vasantrai Mehta holding the highest stake at 27.51%. Additionally, 11 Foreign Institutional Investors (FIIs) collectively hold 18.45% of the shares. The highest public shareholder is Multitude Growth Funds Limited, which owns 5.52%. Individual investors also have a significant presence, holding 18.18% of the company's shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

How big is Sudarshan Pharma?

As of 24th July, Sudarshan Pharma Industries Ltd has a market capitalization of 664.00 Cr, classifying it as a Micro Cap. Recent financial data for Net Sales and Net Profit is unavailable, with Shareholder's Funds at 131.48 Cr and Total Assets at 402.41 Cr as of March 2025.

As of 24th July, <BR><BR>Market Cap: Sudarshan Pharma Industries Ltd has a market capitalization of 664.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 131.48 Cr and Total Assets totaling 402.41 Cr.

When is the next results date for Sudarshan Pharma?

The next results date for Sudarshan Pharma is 18 October 2025.

The next results date for Sudarshan Pharma is scheduled for 18 October 2025.

How has been the historical performance of Sudarshan Pharma?

Sudarshan Pharma has shown consistent growth from March 2022 to March 2025, with net sales increasing from 357.09 Cr to 505.05 Cr, and profit after tax rising from 5.25 Cr to 15.95 Cr, alongside significant improvements in operating cash flow and total assets. The company's financial performance reflects a strong upward trend in sales, profitability, and asset growth.

Answer:<BR>The historical performance of Sudarshan Pharma shows a consistent growth trajectory in net sales and profits over the past four years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Sudarshan Pharma's net sales increased from 357.09 Cr in March 2022 to 505.05 Cr in March 2025, reflecting a robust growth trend. Total operating income followed a similar pattern, rising from 357.09 Cr in March 2022 to 505.05 Cr in March 2025. The company's operating profit (PBDIT) also saw significant growth, climbing from 11.38 Cr in March 2022 to 42.44 Cr in March 2025, while the profit before tax rose from 7.14 Cr to 21.63 Cr in the same period. Consequently, profit after tax increased from 5.25 Cr in March 2022 to 15.95 Cr in March 2025, indicating improved profitability. The company's total assets grew substantially from 137.52 Cr in March 2022 to 402.41 Cr in March 2025, driven by increases in both current and non-current assets. Total liabilities also rose, from 137.52 Cr to 402.41 Cr, primarily due to higher short-term borrowings, which increased from 25.65 Cr to 160.27 Cr. Cash flow from operating activities improved significantly, moving from a negative 3 Cr in March 2022 to a positive 35 Cr in March 2025, highlighting enhanced operational efficiency. Overall, Sudarshan Pharma's financial performance demonstrates a strong upward trend in sales, profitability, and asset growth over the analyzed period.

Is Sudarshan Pharma overvalued or undervalued?

As of November 10, 2025, Sudarshan Pharma is considered very expensive and overvalued with a PE ratio of 42.23, significantly underperforming the market with a 36.43% decline year-to-date, compared to its peers like Sun Pharma and Divi's Lab.

As of 10 November 2025, Sudarshan Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 42.23, an EV to EBITDA of 22.69, and a PEG ratio of 1.01. These figures suggest that the stock is trading at a premium compared to its earnings and growth potential.<BR><BR>In comparison to its peers, Sudarshan Pharma's valuation stands out, with Sun Pharma at a PE of 35.15 and Divi's Lab at a staggering 71.55, both categorized as very expensive. Other competitors like Cipla and Dr. Reddy's Labs are considered attractive, with PE ratios of 22.45 and 17.33, respectively. The stark contrast in valuation metrics highlights Sudarshan Pharma's overvaluation. Additionally, the company's stock has underperformed significantly year-to-date, down 36.43%, compared to a 6.91% gain in the Sensex, reinforcing the notion that it is overvalued in the current market environment.

Is Sudarshan Pharma technically bullish or bearish?

As of December 4, 2025, Sudarshan Pharma's technical trend is mildly bearish, with indicators like the MACD and moving averages supporting this outlook, despite some mild bullishness from the KST and a neutral RSI.

As of 4 December 2025, the technical trend for Sudarshan Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating bearish momentum and the moving averages also reflecting a mildly bearish outlook. The Bollinger Bands confirm this sentiment on both weekly and monthly time frames. Although the KST shows mild bullishness weekly, it is not strong enough to counter the overall bearish indicators. The RSI shows no signal, indicating a lack of momentum in either direction. Overall, the technical indicators suggest a cautious approach given the prevailing mildly bearish conditions.

Why is Sudarshan Pharma Industries Ltd falling/rising?

As of 18-Jan, Sudarshan Pharma Industries Ltd's stock price is at 22.88, down 0.95%, reflecting a bearish trend with a 49.20% decline over the past year. The stock is underperforming against moving averages and experiencing reduced investor interest, compounded by a decrease in institutional holdings, indicating a lack of confidence in its prospects.

As of 18-Jan, Sudarshan Pharma Industries Ltd's stock price is falling, currently at 22.88, reflecting a decrease of 0.22 or 0.95%. The stock has been on a downward trend, having lost 5.42% over the past three days. This decline is further evidenced by its performance over various periods, with a significant drop of 49.20% over the last year, while the benchmark Sensex has increased by 8.47% during the same timeframe.<BR><BR>The stock is trading below its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume on January 14 falling by 67.39% compared to the 5-day average. This suggests a lack of interest from investors, which can contribute to downward pressure on the stock price.<BR><BR>Institutional investors have also reduced their stake in the company by 1.01% in the previous quarter, now holding 19.83% of the company. This decrease in institutional investment can signal a lack of confidence in the stock's prospects, further exacerbating its decline. Despite some positive long-term growth indicators, such as a 51.12% annual growth rate in operating profit and a PEG ratio of 0.8, the recent flat results and significant drop in profit before tax (PBT) by 42.8% compared to the previous four-quarter average have raised concerns among investors.<BR><BR>Overall, the combination of poor recent performance, declining investor participation, and negative sentiment among institutional investors contributes to the falling stock price of Sudarshan Pharma Industries Ltd.

Which are the latest news on Sudarshan Pharma?